Drug Profile
Research programme: phenylketonuria therapeutic lentivirus - American Gene Technologies
Alternative Names: AGT-324Latest Information Update: 20 Nov 2020
Price :
$50
*
At a glance
- Originator American Gene Technologies International
- Developer American Gene Technologies International; University of Pittsburgh Medical Center
- Class Gene therapies
- Mechanism of Action Enzyme replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Phenylketonuria
Most Recent Events
- 10 Nov 2020 American Gene Technologies plans a phase I trial for Phenylketonuria in 2022
- 28 Sep 2020 No recent reports of development identified for preclinical development in Phenylketonuria in USA
- 21 May 2019 Research programme: phenylketonuria therapeutic lentivirus receives Orphan Drug status for Phenylketonuria in USA